Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Biohaven Pharma (BHVN) Tops Q2 EPS by 6c, Revenues Beat
August 10, 2020 7:47 AM EDTBiohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($2.55), $0.06 better than the analyst estimate of ($2.61). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $7.65 million.
Vlad Coric, M.D. Chief Executive Officer, commented, "This has been an... More



